This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .
Treatment of angina pectoris with dipyridamole: a long-term double blind study.
Abstract In a double blind study of 7 months ' duration , 56 patients with chronic angina pectoris associated with ischemic heart disease received dipyridamole ( 50 mg tid ) or placebo in carefully r and omized order . Patients were observed for 4 months while on previous medication , usually nitrates , to determine baseline values . They were also followed for 2 months without any long-acting vasodilator drugs after completion of the double blind study . Of 28 patients on dipyridamole  , 22 ( 78.6 per cent ) had a satisfactory ( excellent or good ) clinical response , 1 had a fair response , and 5 responded poorly . In 28 on  placebo  , response was satisfactory in none , fair in 3 , and poor in 25 . Response to the drug was statistically highly significant compared to placebo , P The first signs of improvement occurred after 2 or 3 months of therapy , with maximal improvement at 3 to 6 months . In most of the satisfactory responses , anginal attacks disappeared completely , nitroglycerin was no longer required , and walking distance increased 4–6-fold . Prolonged dipyridamole therapy usually produced a greater beneficial effect than the previous use of long-acting nitrates . No adverse reactions were experienced on the drug or on placebo . This double blind study appears to confirm the results of previous investigations and demonstrates that dipyridamole is an effective , well tolerated agent for long-term treatment of angina pectoris . It is sometimes of benefit in patients unresponsive to other vasodilator drugs
This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .